pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,551
stories
14h
Will the first approved psychedelic become a blockbuster?
biopharma dive
18h
FDA will miss rare decision deadline for Savara candidate after three-month delay
biospace
19h
As part of sales reorganization, Novo will cut 215 employees at US HQ
biospace
19h
RevMed pads Rasonque’s first-line survival advantage in pancreatic cancer with early data
biospace
19h
An Insmed takeout by Sanofi would be ‘clear strategic fit’ in respiratory space
biospace
20h
Researchers explore possibility of a CTE blood test
stat
21h
Celldex drug stumbles in eczema; Epigenetic editing startup cuts staff
biopharma dive
22h
This week in charts: Biotech investors’ China bets are already paying off
biopharma dive
1d
FDA pushes decision on Belite’s eye disease pill back to May
fiercebiotech
1d
Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
fiercebiotech
1d
Bausch + Lomb and Celldex rocked by respective phase 2 flops
fiercebiotech
1d
Sanofi's Infilbray wins first approval for neurological symptoms of Gaucher
endpoints
1d
Sanofi gains FDA clearance for Gaucher disease pill
biopharma dive
1d
STAT+: Peptide market poised to explode with new Hims and Noom launches
stat
1d
Sanofi considering a deal to acquire Insmed, according to report
endpoints
1d
Anthropic board director Vas Narasimhan bets AI can help Novartis solve ‘biological latency’
fiercebiotech
1d
Actinogen’s sole drug fails pivotal Alzheimer’s study, sinking stock 80%
biospace
1d
Regeneron racks up another first as FDA greenlights generalized myasthenia gravis RNA drug
biospace
1d
With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
biopharma dive
1d
Sanofi secures first FDA approval to treat neurological symptoms in rare metabolic disease
biospace
1d
Regeneron enters neurology field as FDA approves siRNA for myasthenia gravis
endpoints
1d
STAT+: Pharmalittle: We’re reading about a Merck AI deal, China and the pharma supply chain, and more
stat
2d
nChroma halves headcount, calls time on trial of potential HBV ‘cure’
fiercebiotech
2d
Isomorphic adds Merck to AI drug discovery roster days after $5B raise
fiercebiotech
2d
Recon: FDA approves drugs for four rare diseases; Pfizer signs $2.6B licensing deal in China for in vivo CAR-T
raps
2d
More drugmakers look to standalone medical devices for combo products
raps
2d
FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease
fda press
2d
‘Selling and marketing snake oil’: The debate over compounded GLP-1s
biopharma dive
2d
White House pulls nomination for FDA nominee Overton
biopharma dive
2d
CTAD 2026: BMS’ Cobenfy eases Alzheimer’s psychosis as expected but safety events raise questions
biospace
← prev
page 1 of 52
next →